Since last few years a popularity of new oral anticoagulants significantly raised. There are following main direct oral anticoagulants (DOAC) used in therapy: Dabigatran, Rywaroxaban, Apixaban, Endoxaban. Dabigatran (Pradaxa) is the first oral direct thrombin inhibitor approved by FDA in stroke prevention in atrial fibrillation (AF). Anticoagulant effect occurs through direct thrombin binding. Unlike the vitamin K antagonists such as warfarin or acenokumarol, therapy with dabigatran has faster onset and offset action, doesn’t require routine monitoring has much less interactions. The main problem of treatment with dabigatran was difficulty in reversal of anticoagulant effect and overdose. Since three years the new antidote for dabigatran is available – Idarucizumab (Praxbind). Main indications for such use are dabigatran overdose, need of fast effect reversal before any interventions and life threatening bleeding. Despite other ways of anticoagulant effect reversal such as transfusion of plasma coagulation factors Idarucizumab is still highly recommended for direct use.
Aim of this study is to review the new way of dabigatran reversal - Idarucizumab .

Dabigatran; DOAC; Idarucizumab; Praxbind

Wienen W, Stassen JM, Priepke H. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007;98:155–162.

Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study) Am J Cardiol. 2007;100:1419–1426

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. 

Redondo, Santiago et al. “Pharmacological basis and clinical evidence of dabigatran therapy” Journal of hematology & oncology vol. 4 53. 21 Dec. 2011.

 National Guideline Clearinghouse. Guideline for the management of bleeding on dabigatran (Pradaxa) Feb 9, 2012.

Majeed A, Hwang H-G, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128(21):2325–2332

Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–1579. 

Goriacko, Pavel et al. “The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series” P & T : a peer-reviewed journal for formulary management vol. 42,11 (2017): 699-703.

Pruszczyk P, Tomaszuk-Kazberuk A, Słowik A, et al. Management of bleeding or urgent interventions in patients treated with direct oral anticoagulants: 2017 recommendations for Poland. Pol Arch Intern Med. 2017;31;127(5):343-351.

Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121(18):3554–3562.

Eikelboom JW, Quinlan DJ, van Ryn J, et al. Idarucizumab: the antidote for reversal of dabigatran. Circulation. 2015;132(25):2412–2422.

Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113(5):943–951.

Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo controlled, double-blind phase 1 trial. Lancet. 2015;386(9994):680–690.

Pollack Jr, Charles V., et al. "Idarucizumab for dabigatran reversal—full cohort analysis." New England Journal of Medicine377.5 (2017): 431-441.

Crowther, Mark, and Adam Cuker. "How to reverse bleeding in patients on direct oral anticoagulants?." Kardiologia Polska (Polish Heart Journal) (2018).

Mazur P, Darocha T, Filip G, et al. Idarucizumab for dabigatran reversal in patients with atrial fibrillation undergoing emergency surgery for acute aortic syndrome. Pol Arch Med Wewn. 2016; 126(7-8): 579–581,